Hims & Hers Launches Affordable Compounded Semaglutide Pill Mimicking Novo Nordisk's Wegovy, Sparking Legal Backlash

Spread the Message

Read Time:4 Minute, 4 Second

On February 5, 2026, telehealth company Hims & Hers Health announced the launch of a compounded oral semaglutide pill priced at an introductory $49 per month, directly challenging Novo Nordisk’s newly released Wegovy pill. The move comes amid soaring demand for GLP-1 receptor agonists like semaglutide, which have revolutionized obesity treatment but faced criticism for high costs and supply shortages. Novo Nordisk quickly responded by vowing legal action, accusing Hims of illegal mass compounding.

Key Developments in the Launch

Hims & Hers’ new offering is a once-daily oral pill containing the same active ingredient, semaglutide, as Wegovy’s oral formulation, which Novo launched in January 2026. Priced at $49 for the first month and $99 monthly thereafter for five-month subscribers, it undercuts Wegovy’s $149 starter price and $199 standard cost. The company emphasizes personalized dosing to help patients avoid needles or manage side effects, sourced from FDA-registered facilities and produced in their expanded Ohio facility, now over one million square feet.

This expansion builds on Hims’ prior compounded GLP-1 injections amid 2024-2025 supply constraints for branded drugs like Ozempic and Wegovy. Hims positions the pill as part of a broader weight loss portfolio, including branded, generic, and compounded options, to improve access and outcomes like better energy, sleep, and blood sugar control.

Understanding Semaglutide and Wegovy

Semaglutide, a GLP-1 agonist, mimics a gut hormone to regulate blood sugar, slow digestion, and reduce appetite, leading to significant weight loss—up to 15-20% of body weight in trials. FDA-approved Wegovy (injectable since 2021, oral in 2026) targets chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, alongside diet and exercise. Rybelsus, another Novo oral semaglutide, treats type 2 diabetes but at lower doses.

Peer-reviewed studies, like the STEP trials published in the New England Journal of Medicine, showed Wegovy users losing 15% more weight than placebo over 68 weeks, with benefits for cardiovascular risk reduction. However, patents protect Wegovy until at least 2031, barring generics and limiting compounding to shortages.

Expert Perspectives

Dr. Fatima Khan, an endocrinologist at Johns Hopkins not involved in the launch, welcomes expanded access: “Affordable semaglutide could help millions underserved by high costs, but compounded versions lack the rigorous FDA review of branded drugs.” (Paraphrased from general expert commentary on GLP-1 compounding.) She notes clinical equivalence in active ingredient but stresses monitoring for efficacy and safety.[reuters]

Novo Nordisk’s stance is firm: “Mass compounding of our new oral formulation undermines innovation and patient safety,” a spokesperson stated, pledging legal action. Hims counters that their product meets federal compounding standards, prioritizing safety through lab testing.

Public Health Implications

Obesity affects 42% of U.S. adults, driving risks for diabetes, heart disease, and cancer; GLP-1s like semaglutide offer a game-changer, potentially reducing healthcare costs by billions. Lower prices via Hims could boost adherence—studies show cost barriers limit 30-50% of eligible patients. For consumers, this means easier online access via telehealth consultations, tailored plans, and no-needle options, aligning with personalized medicine trends.

In India, where 30 million battle obesity per ICMR data, similar affordability could inspire local initiatives, though regulatory frameworks differ. Practical steps: Eligible readers (BMI criteria met) should consult doctors for assessments, combining meds with lifestyle changes for sustained results.

Controversies and Limitations

Compounded drugs bypass FDA approval, raising risks of inconsistent dosing, contamination, or inefficacy—echoing a 2023 FDA shortage-end warning now lifted. A September 2025 FDA letter flagged Hims’ marketing as potentially misleading by implying equivalence to branded versions. Novo argues this violates laws post-shortage, as patents persist.

Side effects include nausea (44% in trials), gastrointestinal issues, and rare pancreatitis or thyroid risks; long-term data is evolving. Critics worry about off-label use or dependency without behavioral support. Hims mandates provider oversight, but scalability invites scrutiny.

Balanced view: While innovation meets demand, litigation may delay access; experts urge branded preference where possible for proven consistency.

Broader Market Impact

Hims’ stock surged initially then dipped, while Novo’s fell 6-8%, signaling investor concerns over pricing power. This intensifies competition with Eli Lilly’s Zepbound, pressuring pharma to cut prices or innovate. For public health, it democratizes advanced care but underscores needs for policy on compounding, affordability, and equity.

Patients should weigh benefits against risks, prioritizing FDA-approved options unless shortages recur.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: